Anavex Life Sciences Corp (AVXL)

[sokol]

Investor, thank you for wading through the patent. Most interesting examples. Intermittent dosing and periods involved (6months in example 1) raise intriguing questions such as whether the SR1/muscarinic agonist Blarcamesine does in fact result in restoring the body to function in a state of homeostasis - to seek and maintain a condition of equilibrium or stability compared to its dysfunctional state brought about by aging and associated health problems?

We have a lot to learn. Hopefully, we will begin to receive more information and data.